亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

山東誠創醫藥技術開發有限公司  

醫藥化工中間體 ,精細化學品

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:劉曉敏
  • 電話:0531-82316086
  • 郵件:ccyychem@163.com
  • 傳真:0531-82316089
  • QQ:1975868956
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 頭孢洛林中間體(CAS:75028-24-9)
頭孢洛林中間體(CAS:75028-24-9)
單價 面議對比
詢價 暫無
發貨 山東濟南市付款后48小時內
過期 長期有效
更新 2015-08-22 16:02
 
詳細信息

(Z)-2-(5-氨基-1,2,4-噻二唑-3-)-2-乙氧基亞氨基乙酸
英文名:(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-ethoxyiminoacetic acid
CAS: 75028-24-9
質量標準:企標
包裝:25Kg/紙板桶
 
2-巰基-4-(4-吡啶基)噻唑
英文名:4-(4-Pyridinyl)thiazole-2-thiol
CAS: 77168-63-9
質量標準:企標
包裝:25Kg/紙板桶
 
頭孢洛林母核(二禁發 鹽酸化物CAS: 400827-64-7
中文名:7β-氨基-3-[4-(1-甲基-4-吡啶鎓)-2-噻唑硫基]-3-頭孢烯-4-羧酸﹒二禁發 鹽酸化物
英文名:7 β - amino - 3 - [4 - pyridyl - 2 - thiazole sulfur radical ] - 3 - cephem - 4 - carboxylic acid ·2HCl
CAS: 400827-64-7
質量標準:企標
包裝:25Kg/紙板桶
©2025 山東誠創醫藥技術開發有限公司 版權所有   技術支持:化工網   訪問量:6048  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |